• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Dupilumab strengthens HSV-1 specific immune responses in atopic dermatitis
CONCLUSION: Our findings suggest that dupilumab may improve the HSV-1-specific immune response in AD due to an increased type I immune response and a reduction of HSV-1-specific IgE.PMID:37660986 | DOI:10.1016/j.jaci.2023.08.024
Source: Herpes - September 3, 2023 Category: Infectious Diseases Authors: Stephan Traidl Leonard Harries Petra Kienlin Gabriele Begemann Lennart M Roesner Thomas Werfel Source Type: research

Dupilumab strengthens herpes simplex virus type 1 –specific immune responses in atopic dermatitis
Atopic dermatitis (AD), one of the most prevalent chronic inflammatory skin diseases, is orchestrated by a complex pathophysiology influenced by the immune system and skin barrier; it is influenced by environmental factors.1 Altered immune response is marked by type 2 inflammation, with a key role for TH2 cells, but it occurs especially in the chronic phase TH1 and TH17 responses as well.2,3 Moderately and severely affected AD patients are particularly prone to bacterial, fungal, and viral infections.
Source: Journal of Allergy and Clinical Immunology - September 1, 2023 Category: Allergy & Immunology Authors: Stephan Traidl, Leonard Harries, Petra Kienlin, Gabriele Begemann, Lennart M. Roesner, Thomas Werfel Source Type: research

Stevens-johnson Syndrome and Toxic Epidermal Necrolysis: An Overview of Diagnosis, Therapy Options and Prognosis of Patients
Recent Adv Inflamm Allergy Drug Discov. 2023 Aug 21. doi: 10.2174/2772270817666230821102441. Online ahead of print.ABSTRACTBoth Stevens-Johnson syndrome (SJS) and Toxic-epidermal necrolysis (TEN) are generally medication-induced pathological conditions that mostly affect the epidermis and mucus membranes. Nearly 1 to 2 patients per 1,000,000 population are affected annually with SJS and TEN, and sometimes these maladies can cause serious life-threatening events. The reported death rates for SJS range from 1 to 5%, and 25 to 35% for TEN. The mortality risk may even be higher among elderly patients, especially in those who a...
Source: Herpes - August 22, 2023 Category: Infectious Diseases Authors: Vivek Kumar Garg Harpal S Buttar Sajad Ahmad Bhat Nuftieva Ainur Tannu Priya Dharambir Kashyap Hardeep Singh Tuli Source Type: research

Investigating the Safety and Efficacy of the Synthetic Drug Herbix on Immune Responses Involved in the Treatment of a Mouse Model of Herpes Simplex Virus
In this study, 25 male BALB/c mice were used to conduct a mouse model of herpes by subcutaneously injecting an HSV-1 suspension (100 µL of 1× PFU/mL). The mice were divided into 5 groups with groups 1 to 3 designated as intervention groups, and groups 4 and 5 serving as positive and negative control groups, respectively. After 2 days of virus inoculation, the mice were treated with different concentrations of Herbix (100, 200, and 300 mg/mL) via subcutaneous injection. Mice Blood samples (0.5 to 1 mL) were taken from the mice before and after the experiments, and after three-week follow-up period, the mice were sacrifice...
Source: Iranian Journal of Allergy, Asthma and Immunology - April 1, 2023 Category: Allergy & Immunology Authors: Mohammad Ali Khodadoust Gholam Reza Keramatian Najmeh Kaffash Farkhad Jalil Tavakol-Afshari Source Type: research

Pages: 1  2  3  4  5  6  7  8  9  10  11  12  13  14